PT  - JOURNAL ARTICLE
AU  - Peikert, Kevin
AU  - Spranger, Adrian
AU  - Miltenberger-Miltenyi, Gabriel
AU  - Glaß, Hannes
AU  - Falkenburger, Björn
AU  - Klose, Christian
AU  - Tyteca, Donatienne
AU  - Hermann, Andreas
TI  - Phosphatidylethanolamines are the main lipid class altered in red blood cells from patients with VPS13A disease/chorea-acanthocytosis
AID  - 10.1101/2024.09.01.24312543
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.09.01.24312543
4099  - http://medrxiv.org/content/early/2024/09/01/2024.09.01.24312543.short
4100  - http://medrxiv.org/content/early/2024/09/01/2024.09.01.24312543.full
AB  - Background VPS13A disease (chorea-acanthocytosis) is an ultra-rare disorder caused by loss of function mutations in VPS13A characterized by striatal degeneration and by red blood cell (RBC) acanthocytosis. VPS13A is a bridge-like protein mediating bulk lipid transfer at membrane contact sites.Objectives To assess the lipid composition of patient-derived RBCs.Methods RBCs collected from 5 VPS13A disease patients and 12 control subjects were analyzed by mass spectrometry (lipidomics).Results While we found no significant differences on the overall lipid class level, alterations in certain species were detected: phosphatidylethanolamine species with both longer chain length and higher unsaturation were increased in VPS13A disease samples. Specific ceramide, phosphatidylcholine and sphingomyelin species were also altered.Conclusions The presented alterations of particular lipid species in RBCs in VPS13A disease contribute to 1) the understanding of acanthocyte formation and 2) future biomarker identification. Lipid distribution seems to play a key role in the pathophysiology of VPS13A disease.Competing Interest StatementCK is CTO and shareholder of Lipotype GmbHFunding StatementThis study was funded by the MeDDrive grant (TU Dresden).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the ethics committee at the Technische Universitaet Dresden (EK45022009, EK78022015).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors